Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.

Cancer Med · 2015 · PMC4329001 · PMID 25417601

Europe PMC DOI

hedged sentence

0.7849

closest p · 15.7× alpha

0.7849

boldest claim

The sentences

did not reach statistical significanceP = 0.7849not close (p > 0.1)

Although serum metformin appeared to be more elevated in the responder group than the nonresponder group posttreatment, a single outlier within the responder group drove this seeming difference that did not reach statistical significance ( P = 0.7849).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.